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Abstract  The aim of this study was to determine fatty acid composition in periprostatic adipose tissue (PPAT) of patients 
undergoing surgery for either prostatic cancer or benign prostatic hyperplasia (BPH). PPAT were obtained from 12 patients 
undergoing radical prostatectomy for clinically localized prostate tumors (TPPAT, age range 55-70 years) and 11 patients 
undergoing adenomectomy for BPH (BPPAT, age range 57-79 years). Fatty acid methyl esters of total lipids of PPAT were 
processed and then analyzed by gas chromatography-mass spectrometry. Quantitation was performed by comparing the 
percentage area of each FAME peak on the chromatogram with that of the internal standard of known weight, and expressed 
as percentage of total fatty acids. There were differences in fatty acid content of PPAT, with higher levels of palmitic acid 
(16:0; P = 0.036) and dihomo-gammalinolenic acid (20:3 n-6; P = 0.020) and lower levels of arachidonic acid (20:4 n-6; P = 
0.030) in prostate cancer PPAT, along with a higher 20:4/20:3 (P = 0.001) and lower 20:3/18:2 (P = 0.027) fatty acid ratio in 
benign prostate hyperplasia PPAT. To the best of our knowledge, this study represents the first attempt at comparing 
periprostatic fat pad lipid composition in different prostate pathologies. Fatty acid analysis and lipidomics may be important 
tools to further understand events that occur in tumor microenvironment during prostate cancer disease. 




According to statistics from the Argentine Ministry of 
Health, prostate cancer (PCa) is the most relevant cancer for 
males in Argentina and the second greatest cause of cancer 
mortality in men [1]. 
There is an urgent need to find new and reliable 
biomarkers for this disease due to the limitations of 
currently available methods of detection. Lipids are known 
to be involved in many biological pathways and 
modification of cell lipid composition can lead to severe 
pathologies. Lipidomics is becoming an expanding field of 
research, and the increased volume of study in this area may 
well contribute to the discovery of new biomarkers for 
several diseases including cancer [2, 3]. 
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Epidemiological studies have reported on the effect of 
dietary fat on prostate cancer risk [4-6]. However, the 
mechanistic role of dietary fat in PCa remains ill defined. 
Dietary fat includes n-3 and n-6 polyunsaturated fatty acids 
(PUFAs), both of which play important roles in many 
human biological processes, including PCa [7]. Because 
humans cannot synthesize n-3 and n-6 PUFAs, they are 
considered essential fatty acids. All mammalian cells can 
interconvert the PUFAs within each series by elongation, 
desaturation, and retro conversion, but the two series are not 
interchangeable. n-3 and n-6 PUFAs can be metabolized by 
cyclooxygenase (COX) and lipoxygenases (LOX); the 
resulting eicosanoids have been implicated in the 
pathogenesis of a variety of human diseases, including 
cancer. n-6 derived prostaglandins (PGs), especially PGE2 
derived from the metabolism of arachidonic acid (AA, 20:4 
n-6), are strongly implicated in tumor growth and 
metastasis, inhibiting apoptosis and enhancing angiogenesis 
[8, 9]. 
To date, very little is known about the cross-talk between 
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adipose tissue and prostate cancer cells. Periprostatic 
adipose tissue (PPAT) surrounds the prostate gland and is 
part of tumor microenvironment. PPAT thickness has been 
associated with PCa aggressiveness [10] and high-grade 
PCa diagnosis [11] and furthermore, factors secreted by 
PPAT have been shown to induce a favorable 
microenvironment for PCa progression [12, 13]. Results 
from our laboratory have shown that PPAT derived factors 
could modulate disease progression in the early stages of 
PCa [14]. Recently, a gene expression signature study of 
PPAT suggested that the local environment could be 
allowing cancer progression in obese men exhibiting an 
anti-lipolytic and adipo/lipogenic gene expression profile 
[15]. 
The aim of the present study was to evaluate if specific 
fatty acids in PPAT could modify PCa development. 
Despite the small number of patients analyzed, to our 
knowledge this is the first report on the analysis and 
comparison of fatty acid composition of PPAT in PCa and 
benign prostatic hyperplasia (BPH) patients.  
2. Materials and Methods 
Human PPAT was obtained from 23 patients attending 
the Urology Department, Hospital de Clínicas “José de San 
Martín”, Buenos Aires, Argentina. Twelve patients 
underwent radical prostatectomy for clinically localized 
prostate tumors (TPPAT, age range 55-70 years), and 11 
patients underwent adenomectomy for BPH (BPPAT, age 
range 57-79 years). None of the patients had received 
preoperative therapy. Patients gave their written consent for 
tissue harvesting for this study and all experimental 
procedures were approved by IBYME (Instituto de Biología 
y Medicina Experimental) Ethics Committee. 
Table 1.  Clinicopathological Characteristics of Patients 
 BPH PCa P value 
Age (years) 67.6 ± 6.4 62.5 ± 5.1 0.046 
Body mass index (kg/m2) 26.8 ± 3.8 28.8 ± 4.2 0.241 
Pathology stage*    
Localized (T2)  66.7 %  
Advanced (T3)  33.3 %  
Gleason score    
< 7 (3+3)  50 %  
>= (3+4, 4+3, 4+5)  50 %  
Data Presented as Mean ± Standard Deviation; Differences Among Groups Were 
Calculated Using t-Test 
*Data Presented as Percentage of Cases BPH, Benign Prostate Hyperplasia 
Patients; Pca, Prostate Cancer Patients 
In each patient, once the anterior surface of the prostate 
had been surgically exposed, the fat tissue surrounding the 
superficial venous plexus of Santorini was dissected. A 
fatty, loose tissue surrounds this plexus on both sides of the 
inferior portion of the anterior surface of the prostate, and 
approximately 30 – 50 mg of this fat tissue was separated 
for further processing. 
Clinical features of the patients (age, body mass index) 
and pathological characteristics of the specimens used 
(Gleason score and pathological stage (pT)) are shown in 
Table 1. All BPH specimens showed histological epithelial 
and/or stromal cell hyperplasia but no malignant cells. 
Body mass index (BMI) was calculated and patients 
classified as overweight (BMI ≥ 25.00 kg/m2) or obese 
(BMI ≥ 30.00 kg/m2) according to World Health 
Organization (WHO) guidelines. 
Total lipid extraction from each sample was carried out 
according to the method of Folch et al. [16]. Lipid species 
were identified by TLC and compared with standards of a 
mixture of mono, di- and triacylglycerides (Supelco, USA) 
and a mixture of phospholipids (Sigma Aldrich Co., St 
Louis, MO, USA). Analytical TLC was performed on 
precoated silica gel 60 F254 (0.2 mm, Merck) using 
cyclohexane: acetone (70:30) for mono, di- and 
triacylglycerides and chloroform: methanol: ammonium 
hydroxide (65:35:5) for phospholipids. Fatty acid methyl 
esters (FAMEs) of total lipids of PPAT were prepared by 
reaction with 10% acetyl chloride in methanol at 70ºC for 2 
h. After cooling, water was added and the FAMEs were 
extracted with chloroform and purified through a 500 mg 
StrataTM SI-1 cartridge of silica gel (55 μm) (Phenomenex). 
The purified FAMEs were analyzed by gas 
chromatography-mass spectrometry on a Shimadzu 
GCMS-QP5050 A equipped with an Ultra 2 capillary 
column (50 m x 0.20 mm I.D., 0.11 µm thickness). Helium 
was the carrier gas. Both injector and detector temperatures 
were set at 280°C; oven temperature was programmed from 
100 to 280°C at a rate of 5°C/min and 10 min at 280°C. 
FAMEs were also analyzed by gas chromatography on a 
Thermal chromatograph equipped with a DB-225 capillary 
column (15 m x 0.25 mm I.D., 0.25 µm thickness). 
Nitrogen was the carrier gas. Both injector and detector 
temperatures were set at 280°C. Rise in column temperature 
was programmed from 37°C to 195°C at a rate of 24°C /min 
and stable at 195°C for 1 min, then at a rate of 3ºC/min up 
to 205°C stable at this temperature for one min, then at a 
rate of 8ºC/min up to 230°C/min and stable at 230°C for 35 
min. Individual components were identified using mass 
spectral data and by comparing retention time data with 
those obtained for authentic laboratory standards. 
Quantitation was performed by comparing the % area of 
each FAME peak on the chromatogram with that of the 
internal standard (nonadecanoate, Sigma-Aldrich Co., St 
Louis, MO, USA) of known weight, and expressed as 
percentage of total fatty acids. 
The activities of enzymes involved in fatty acid 
biosynthesis were estimated as the product-to-precursor 
ratios of the percentages of individual fatty acids [17].  
The data were analyzed using Graph Pad Prism 5 
software (La Jolla, CA, USA). Data are presented as mean 
± standard deviation. Departure from normality was tested 
using Shapiro-Wilk test. Unpaired t-test or Mann-Whitney 
test was used for statistical comparison between means. A 
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statistical significant difference was considered to be 
present at P < 0.05. 
3. Results 
PPAT samples from 23 patients were analyzed. Patients 
either underwent radical prostatectomy for clinically 
localized prostate tumors (TPPAT, n=12) or had 
adenomectomy for BPH (BPPAT, n=11). PCa patients had 
a mean age of 62.5 ± 5.1 years, significantly lower than 
BPH patients: 67.6 ± 6.4 years (Table 1). 
BMI was slightly higher, though not statistically 
significant, in subjects with PCa (n=11, patient 12 without 
BMI data) compared to those in the BPH group (28.8 ± 4.2 
kg/m2 vs 26.8 ± 3.8 kg/m2, P = 0.241). Both groups had a 
mean body mass index (BMI) that corresponded to being 
overweight. Patients were further separated into two groups 
based on their BMI according to WHO classification: 
normal (N) and overweight-obese. Overweight and obesity 
was detected in 73% of PCa patients (8 out of 11) and in  
55% of patients with BPH (6 out of 11). Correlation 
between BMI and fatty acid composition could not be 
evaluated due to the low number of PCa patients with a 
normal BMI.  
3.1. Fatty Acid Composition of Periprostatic Adipose 
Tissue 
TLC analysis of lipid fractions obtained from PPAT 
revealed the presence of triacylglycerides as the main 
component. Fatty acid composition of PPAT obtained from 
BPH and PCa patients is summarized in Table 2. Data 
corresponded to both individual fatty acids and to fatty 
acids grouped according to their saturation characteristics: 
saturated (SFA), monounsaturated (MUFA) or 
polyunsaturated (PUFA).  
Fatty acid profile in PPAT was dominated by MUFAs, 
followed by SFAs and PUFAs; mean values for these fatty 
acids in TPPAT and BPPAT were not significantly 
different. 
Table 2.  Fatty Acid (FA) Composition of Periprostatic Adipose Tissue (PPAT) from Patients Undergoing Radical Prostatectomy for Clinically Localized 
Prostate Tumors (TPPAT) and Patients Undergoing Adenomectomy for BPH (BPPAT). (% of Total FA) 
 BPPAT TPPAT P value 
Fatty acids Mean SD Mean SD  
14:0 2.803 0.687 2.643 0.677 0.878 
14:1 0.268 0.114 0.208 0.102 0.069 
15:0 0.357 0.057 0.366 0.069 0.750 
16:0 21.860 1.210 23.220 1.649 0.036* 
16:1(n-7) 4.986 1.479 4.348 1.237 0.124 
17:0 0.402 0.078 0.431 0.072 0.367 
18:0 5.953 0.790 6.045 0.796 0.853 
18:1(n-9) 43.430 1.319 43.250 1.276 0.704 
18:2(n-6) 18.090 2.847 17.380 2.769 0.550 
20:0 0.138 0.053 0.165 0.051 0.147 
20:1 0.732 0.117 0.848 0.197 0.105 
20:2(n-6) 0.217 0.054 0.249 0.058 0.184 
20:3(n-6) 0.188 0.073 0.269 0.081 0.020* 
20:4(n-6) 0.372 0.105 0.284 0.075 0.030* 
22:5 (n-3) 0.128 0.055 0.176 0.065 0.073 
22:6 (n-3) 0.147 0.085 0.140 0.091 0.829 
SAFAa 31.510 2.033 32.870 1.860 0.079 
MUFAb 52.260 5.763 48.650 1.308 0.242 
PUFAc 19.150 2.936 18.050 2.719 0.589 
18:0 / 18:1 0.138 0.020 0.140 0.109 0.974 
20:4 / 18:2 0.021 0.008 0.017 0.006 0.150 
18:0 / 16:0 0.273 0.034 0.260 0.037 0.369 
20:4 / 20:3 2.275 1.411 1.089 0.293 0.001* 
20:3 / 18:2 0.011 0.004 0.016 0.007 0.027* 
n-3 / n-6 0.014 0.006 0.017 0.005 0.679 
a) Saturated Fatty Acids, b) Monounsaturated Fatty Acids, c) Polyunsaturated Fatty Acids. Data Presented as Mean ± Standard Deviation 
Differences Among Groups Were Calculated Using t-Test or Mann-Whitney. 
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Among SFAs, there was a significantly higher proportion 
of palmitic acid in TPPAT (23.22 ± 1.65) than in BPPAT 
(21.86 ± 1.21) (P = 0.036). Stearic acid, also abundant in 
both groups, was not statistically different. 
The main MUFA in both TPPAT and BPPAT was oleic 
acid, with no significant difference in its content between 
groups.  
PUFAs included n-3 and n-6, the two major classes of 
essential dietary fatty acids. Linoleic acid (18:2 n-6) was the 
main n-6 PUFA both in TPPAT and BPPAT, followed by 
arachidonic acid, eicosadienoic acid (20:2 n-6) and 
dihomo-gammalinolenic acid) (DGLA, 20:3 n-6). DGLA 
content was significantly higher in TPPAT than in BPPAT: 
0.27 ± 0.08% vs 0.19 ± 0.07% (P = 0.020) and AA 
concentration was reduced in TPPAT (0.28 ± 0.07) vs 
BPPAT (0.37 ± 0.10) (P = 0.030). No significant 
differences were observed in the concentrations of any other 
fatty acid. AA level in PPAT displayed a moderate inverse 
association with PCa. 
There was a higher 20:4/20:3 ratio in BPPAT (2.28 ± 
1.41) vs TPPAT (1.09 ± 0.29) (P = 0.001) and a lower 
20:3/18:2 ratio in BPPAT (0.011 ± 0.004) vs TPPAT (0.016 
± 0.007) (P = 0.027) suggesting differential activities in 
enzymes related to lipid metabolism. 
4. Discussion 
To our knowledge, this is the first study that clearly 
indicates a difference in fatty acid composition of PPAT 
between patients with benign prostate hyperplasia and PCa. 
The role of lipid metabolism has gained popularity in 
PCa research, and de novo lipogenesis is under intense 
investigation as a therapeutic target [18]. Modification of 
cell lipid composition can lead to severe pathologies. Lipid 
droplets (LD) are inducible organelles constitutively 
expressed in adipocytes. They are involved in neutral lipid 
storage and have roles in cell signaling, regulation of lipid 
metabolism, membrane trafficking and control of the 
synthesis and secretion of inflammatory mediators. 
Enzymes involved in eicosanoid synthesis (COX and LOX) 
are localized in LD and these are sites for eicosanoid 
generation in cells during inflammation and cancer [19].  
We showed that palmitic acid (C16:0) levels were higher 
in TPPAT than in BPPAT, possibly associated with an 
increased expression of fatty acid synthase (FAS), which 
has emerged as a common phenotype to most human 
carcinomas [20]. Palmitic acid is the major fatty acid 
produced by de novo lipogenesis from acetyl CoA and 
malonyl CoA by FAS [21]. Evidence suggests that the 
expression of FAS mRNA and protein are upregulated in 
prostate tumor tissues, an event that occurs early in the 
development of prostate cancer [22]. Under normal 
conditions, de novo fatty acid biosynthesis and FAS 
expression occur constitutively at very low levels, since the 
requirement for fatty acids is sufficiently met by dietary 
intake [21]. On the other hand, immunohistochemical 
studies have reported that FAS protein is overexpressed in 
the majority of human malignancies and their preneoplastic 
lesions, including PCa [23].  
This study has also shown lower levels of AA in TPPAT 
than in BPPAT. AA is the most important PUFA associated 
with membrane phospholipids. The metabolism of this fatty 
acid by either COX or LOX pathway generates eicosanoids, 
which have been implicated in cancer, and are considered 
important in tumor promotion and progression in PCa  [9, 
24]. Increased AA metabolism via the COX, and possibly 
LOX pathway, could explain the lower AA concentration in 
malignant tissue observed in the present study. Preliminary 
in vitro studies have shown that malignant prostatic tissue 
has a greatly increased capacity for eicosanoid synthesis 
from radiolabeled AA compared to benign tissue [24]. A 
lower concentration of AA (measured in the phospholipid 
fraction of both plasma and tissue) has been found in 
subjects with PCa vs BPH, due to an increased metabolism 
via the LOX and COX pathways, and thus producing higher 
concentrations of eicosanoids [25, 26].  
Tissue AA is derived primarily from dietary linoleic acid. 
This conversion is regulated by delta-6-desaturase, an 
enzyme that catalyzes the first step in this metabolic 
pathway [27]. Delta-6-desaturase incorporates a double 
bond at the C-6 carbon of PUFAs and is rate limiting in the 
desaturation and elongation of LA to AA (n-6 family) and 
α-linolenic acid (ALA, 18:3 n-3) to eicosapentaenoic acid 
(EPA, 20:5 n-3) (n-3 family). Delta-6-desaturase converts 
LA to γ-linolenic acid (GLA, 18:3, n-6) and GLA is 
elongated to form DGLA that can then be converted to AA 
by the action of the enzyme delta-5-desaturase. AA is the 
precursor of two series of prostaglandins, thromboxanes and 
four series of leukotrienes (LTs). Similarly, ALA is 
converted to EPA by delta-6-desaturase and 
delta-5-desaturase. EPA is the precursor of three series of 
prostaglandins and five series of LTs and EPA can also be 
elongated to form docosahexaenoic acid (DHA). 
It is probable that the lower amounts of AA found in 
TPPAT in this study were due to the combination of both a 
decreased activity of delta-5-desaturase and an increased 
metabolism via the LOX and COX pathways. There was a 
higher concentration of DGLA in TPPAT as opposed to 
BPPAT, suggesting a lower activity of delta-5-desaturase in 
the latter, which corresponds to what has been previously 
observed in PCa tissue [28]. On the other hand, levels of 
TPPAT fatty acids reported in this study reveal that there 
was no decrease in the activity of delta-6-desaturase, 
contrary to previous observations in PCa tissue [28]. Fatty 
acid ratios in tissue or plasma for different classes of lipids 
have been frequently used as an indication of enzyme 
activity, validating the use of 20:4/20:3 and 20:3/18:2 ratios 
as indicators of desaturase and elongase activities [24]. 
It is noteworthy that FA content and FA ratios were not 
statistically significantly different between patients groups 
for a number of FAs tested. However, this lack of 
significance seems to be more a function of intragroup 
variability (as indicated by large SDs) rather than a 
similarity between PCa and BPH patients. Indeed, the 
 
 Research In Cancer and Tumor 2015, 4(1): 1-6 5 
 
proximity of some of these values to significance suggests 
that they would probably become significantly different if a 
larger number of samples were analyzed. Similarly, the lack 
of correlation between the Gleason score and lipid levels 
could well be the result of the small number of patients 
studied.  
Site-specific differences observed in fatty acid 
composition of PPAT, both by ourselves and by others [29, 
30] suggest that analyzing the fatty acid composition and 
the lipidome may be important for the understanding of 
events that occur in the tumor microenvironment. This, in 
turn, would be helpful to understand which molecules could 
be involved in the cellular mechanisms that regulate PCa 
progression and metastasis.  
5. Conclusions 
We believe this findings show a possible relationship 
between the type of lipids/fatty acids present in the 
periprostatic adipose tissue and the occurrence of prostate 
cancer. Although it is difficult to determine the type of diet 
all those patients had in common, mainly because is no 
usually asked or does not become a significant part of the 
clinical records, a broader study should take this data into 
consideration and that would allow to narrow down the 
molecules possibly involved in cancer progression. 
Arachidonic acid is a well-known lipid second messenger as 
well as a metabolite in biologically active molecules 
(prostaglandins, thromboxanes and leukotrienes, among 
others) and thus could be a good candidate for further study. 
Our work did not focus on enzyme activity, approximated 
only by determining the ratio of substrates and products, 
and we believe this to be a relevant point in any further 
investigation, as well as a direct measurement of 
arachidonic acid metabolites. 
We believe that the analysis of human periprostatic 
adipose tissue from Argentine PCa and BPH patients 
reported on this paper, despite the small number of patients 
analyzed, contributes significantly to furthering our current 
knowledge of PCa occurrence and progression, opening the 
path to further research in the field. 
Additional studies will be conducted in our laboratory 
with a larger number of patients in order to correlate the 
“amount” of fat with the factors produced and / or released 
by PPAT. We believe that both the study of 
adipoparacrinology [31] as well as the “mapping” of fat will 
be a step forward in the study of prostate disease. 
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